Skip to main content
Premium Trial:

Request an Annual Quote

Blockchain-Based LunaDNA Picks Up $2M in Seed Funding

CHICAGO (GenomeWeb) – Startup firm LunaDNA, a blockchain-based genomic and medical research company, said late Monday that it has landed $2 million in seed funding.

Several former Illumina executives were among the group of individual investors, including ex-Illumina Chief Information Officer Scott Kahn, Illumina Cofounder David Walt, and Gavin Saitowitz, CEO and cofounder of Prelude Capital. San Diego-based Luna simultaneously announced that Kahn has been named CIO of the startup.

Luna, which calls itself a public benefit corporation, relies on blockchain technology for security and for rewarding those that contribute data to the research database. Individuals who sell their genetic data will receive compensation in a decentralized cryptocurrency called Luna Coins that the company said have "real monetary value," though Luna did not elaborate on how people could spend such currency.

"Understanding the genome and decoding diseases will take the cooperation of a diverse and large community. While personal DNA testing continues to rise in popularity, currently these data are siloed, hindering genomic discovery," said David Barker, a member of Luna's advisory board and former Illumina CSO. "What makes LunaDNA unique is its consumer empowerment through offering reward and ownership for providing genomic data, which will be used to back scientific research."

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.